$4550
$3640
[Research Report] The gastrointestinal drugs market size is expected to grow from US$ 49,043.38 million in 2019 to US$ 71,300.28 million by 2027; it is estimated to record a CAGR of 4.9% from 2020 to 2027.
Analyst Perspective
Rising investments in the development of biologics and the emergence of a biosimilar are expected to grow at a lucrative rate over the forecast period. Pharmaceutical companies are investing in research and development to discover new and improved gastrointestinal drugs. These are improved gastrointestinal drugs and these advancements have led to the introduction of innovative medications with enhanced efficacy, improved tolerability, and fewer side effects. Newer drugs options provide healthcare providers with more treatment choices and better outcomes for patients. There has been an improvement in medical awareness and diagnostic techniques for gastrointestinal disorder. This has led to earlier and more accurate diagnosis, prompting healthcare providers to prescribe appropriate medications for treatment. With increased awareness among patients, there is also a higher demand for effective drugs to alleviate symptoms and improve quality of life. Additionally, the presence of highly advanced medical care facilities and high healthcare expenditure are boosting the gastrointestinal drugs market growth in various regions.
Market Overview
Gastrointestinal drugs are a category of medications that are used to treat disorders and conditions related to the gastrointestinal system, which includes the organs involved in digestion, absorption, and elimination of food and waste. Various factors can contribute to GI disorder, including infections, inflammation, acid secretion imbalances, ulcers, and other structural abnormalities. Some gastrointestinal disorders involve abnormal mobility, which affects the movement of food through the digestive tract. Drugs that enhance or regulate motility, such as prokinetic agents, can be used to treat conditions like gastroparesis or irritable bowel syndrome (IBS). Also, growing incidences of chronic constipation among all age groups, increasing over-the-counter sales, increasing demand for laxatives, and increasing product offerings from manufacturers contributes to the growth of the gastrointestinal drugs market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Gastrointestinal Drugs Market: Strategic Insights
Market Size Value in US$ 49,043.38 million in 2019 Market Size Value by US$ 71,300.28 Million by 2027 Growth rate CAGR of 5.4% from 2020 to 2027 Forecast Period 2020 - 2027 Base Year 2019
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Gastrointestinal Drugs Market: Strategic Insights
| Market Size Value in | US$ 49,043.38 million in 2019 |
| Market Size Value by | US$ 71,300.28 Million by 2027 |
| Growth rate | CAGR of 5.4% from 2020 to 2027 |
| Forecast Period | 2020 - 2027 |
| Base Year | 2019 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Driver
Increase in Development of Biologics to Drive Global Gastrointestinal Drugs Market Growth
Increasing development of biologics for the treatment of GI diseases is driving the growth of the market. In the last few years, new treatments called biologics are being used for the treatment of inflammatory diseases. Currently, the FDA has approved Humira, Cimzia, Remicade, Simponi, Tysabri, and Entyvio biologics for the treatment of Crohn’s disease and ulcerative colitis. Biologics have revolutionized the IBD treatment, and their success in the treatment of these indications is driving the use of biologics in other GI conditions, such as celiac disease, eosinophilic esophagitis, and autoimmune hepatitis. The development of new medication is driving the growth of the market. For instance, in September 2019, Janssen Pharmaceutical received the European Commission approval for STELARA. It will be used in the treatment of moderately to severely active ulcerative colitis in adults. It is the first biologic treatment that will target the IL-12/IL-23 pathway, an important therapeutic target in UC. Apart from this, strategic initiatives by market players, such as product launch in untapped markets, are further driving the growth of the market. For instance, in July 2020, Takeda Pharmaceutical Company launched its blockbuster biologic drug Vedolizumab in India as part of its GI portfolio. Vedolizumab would be sold in India under the brand name Kynteles. It would be used for the treatment of chronic inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. The cases of GI disorders are on the rise in developing countries. For instance, there are currently around 1.5 million IBD patients in India. The introduction of new biologics in these markets is expected to drive the market growth during the forecast period.
Moreover, along with product launches, the market players are carrying out different strategies to add innovative therapies in their product portfolio. This is further driving the growth of the gastrointestinal drugs market. For instance, in February 2020, Takeda Pharmaceutical Company Limited acquired PvP Biologics, Inc. This acquisition added investigational medicine TAK-062 (Kuma062) in the company's GI portfolio, which would be used for the treatment of uncontrolled celiac disease. The company is planning to submit data from the Phase 1 study for presentation at an upcoming medical congress. Globally, many people are living with celiac disease, and they manage their symptoms by following a gluten-free diet. There is still no treatment for people who experience severe symptoms. With this acquisition, the company is expecting to bring new therapies in the area of celiac disease management
Segmental Analysis
Based on application, the gastrointestinal drugs market is segmented into inflammatory ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastroenteritis, celiac disease, and others. In 2019, the inflammatory ulcerative colitis segment held a larger share of the gastrointestinal drugs market. However, the irritable bowel syndrome segment is anticipated to register the highest CAGR in the gastrointestinal drugs market during the forecast period. The growing prevalence of Ulcerative colitis (UC) is driving the adoption of GI drugs in the forecast period for the gastrointestinal drugs market. As per the study published in NCBI, In the US, 34 children per 100,000 persons have UC, while for adults the prevalence is 263 per 100,000 persons. Also, the growth of this segment can be attributed to easy availability of drugs to treat this condition. In addition, many manufactures have launched a wide range of biologics for UC, which is further driving the growth of the gastrointestinal drugs market. For instance, Takeda Pharmaceuticals, Janssen Pharmaceuticals, and Pfizer are among the top companies that have established themselves in the market with their products for the treatment of inflammatory ulcerative colitis.
Regional Analysis
The Asia- Pacific gastrointestinal drugs market was valued at US$ 8,868.44 million in 2019 and is projected to reach US$ 13,618.35 million by 2027; it is expected to grow at a CAGR of 5.6% during the forecast period. The Asia-Pacific gastrointestinal drugs market is segmented into the China, Japan, India, Australia, South Korea and Rest of Asia Pacific. The Japan held the largest share of the Asia-Pacific gastrointestinal drugs market in 2019. The growth of the gastrointestinal drugs market in the country is primarily driven by growing prevalence of gastrointestinal diseases in Japan which is likely to demand gastrointestinal drugs. As per the study ‘Trends in Gastrointestinal Diseases in Japan’, the incidence of gastric cancer is high in East Asian countries, including Japan. It also reported that incidence of gastroesophageal reflux disease (GERD) and IBD is continuously increasing, which will fuel the growth of gastrointestinal drugs market.
Moreover, new product launches and funding for research purposes also drive the gastrointestinal drugs market growth in the US. For instance, In June 2023, Astellas Pharma Inc. announced the submission of a New Drug Application to Japan's Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. Thus, above mentioned factors are expected to propel the gastrointestinal drugs market growth in the Asia-Pacific region.
Key Player Analysis
The gastrointestinal drugs market analysis consists of players, such as Sanofi, GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Bausch Health, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Celltrion Healthcare Co.,Ltd., and LEXICON PHARMACEUTICALS, INC, among others are the top two players owing to the diversified product portfolio offered.
Recent Developments
Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the gastrointestinal drugs market. A few recent key market developments in the gastrointestinal drugs market are listed below:
- In July 2020, Celltrion Healthcare received marketing authorization approval the European Commission (EC) for Remsima (infliximab, CT-P13). It is a subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis.
- In May 2020, Sanofi a leading manufacturer of brands such as Buscopan for irritable Bowel Syndrome and Dulcolax for constipation relief has entered into the digestive wellbeing market space with the launch of a new food supplement, Buscobiota. Buscobiota comprised of three types of Lactobacillus and two types of Bifidobacterium which can be used as a preventive medication for chronic constipation.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Drug Class, Route of Administration, Application, and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The gastrointestinal drugsmarket majorly consists of the players such as Sanofi, GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Bausch Health, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Celltrion Healthcare Co., Ltd, and LEXICON PHARMACEUTICALS, INC. are among others.
Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits globally. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.
The factors that are driving growth of the market are rise in prevalence of gastrointestinal (GI) diseases and increase in development of biologics are expected to boost the growth of the global gastrointestinal drugsmarket.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Gastrointestinal Drugs Market – By Drug Class
1.3.2 Gastrointestinal Drugs Market – By Route of Administration
1.3.3 Gastrointestinal Drugs Market – By Application
1.3.4 Gastrointestinal Drugs Market – By Distribution Channel
1.3.5 Global Gastrointestinal Drugs Market – By Geography
2. Gastrointestinal Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Gastrointestinal Drugs– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East and Africa (MEA) – PEST Analysis
4.2.5 South and Central America (SCAM) – PEST Analysis
4.3 Expert Opinions
5. Gastrointestinal Drugs Market– Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases
5.1.2 Increase in Development of Biologics
5.2 Market Restraints
5.2.1 Low Awareness Associated with Gastrointestinal Disorders in Low-Income Economies
5.3 Market Opportunities
5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates
5.4 Future Trends
5.4.1 Emergence of Biosimilars
5.5 Impact Analysis
6. Gastrointestinal Drugs Market – Global Analysis
6.1 Global Gastrointestinal Drugs Marker Revenue Forecast And Analysis
6.2 Global Gastrointestinal Drugs Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
7. Gastrointestinal Drugs Market Analysis – By Drug Class
7.1 Overview
7.2 Gastrointestinal Drugs Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Acid Neutralizers
7.3.1 Overview
7.3.2 Acid Neutralizers: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Antidiarrheal and Laxatives
7.4.1 Overview
7.4.2 Antidiarrheal and Laxatives: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Anti-Inflammatory Drugs
7.5.1 Overview
7.5.2 Anti-Inflammatory Drugs: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Antiemetic and Antinauseants
7.6.1 Overview
7.6.2 Antiemetic and Antinauseants: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.7 Biologics
7.7.1 Overview
7.7.2 Biologics: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8. Gastrointestinal Drugs Market Analysis – By Route of Administration
8.1 Overview
8.2 Gastrointestinal Drugs Market Share, by Route of Administration, 2019 and 2027
8.3 Oral
8.3.1 Overview
8.3.2 Oral: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Parenteral
8.4.1 Overview
8.4.2 Parenteral: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9. Gastrointestinal Drugs Market Analysis – By Application
9.1 Overview
9.2 Gastrointestinal Drugs Market Revenue Share, by Application (2019 and 2027)
9.3 Inflammatory Ulcerative Colitis
9.3.1 Overview
9.3.2 Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Crohn's Disease
9.4.1 Overview
9.4.2 Crohn's Disease: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Irritable Bowel Syndrome
9.5.1 Overview
9.5.2 Irritable Bowel Syndrome: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.6 Gastroenteritis
9.6.1 Overview
9.6.2 Gastroenteritis: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.7 Celiac Disease
9.7.1 Overview
9.7.2 Celiac Disease: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
10. Gastrointestinal Drugs Market Analysis – By Distribution Channel
10.1 Overview
10.2 Gastrointestinal Drugs Market Share, by Distribution Channel, 2019 and 2027
10.3 Hospital Pharmacies
10.3.1 Overview
10.3.2 Hospital Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
10.4 Retail Pharmacies
10.4.1 Overview
10.4.2 Retail Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
10.5 Online Pharmacies
10.5.1 Overview
10.5.2 Online Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
11. Gastrointestinal Drugs Market Analysis And Forecast To 2027 – Geographical Analysis
11.1 North America: Gastrointestinal Drugs Market
11.1.1 Overview
11.1.2 North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.3 North America: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.4 North America: Gastrointestinal Drugs Market, by Route of Administration, 2018–2027 (USD Million)
11.1.5 North America: Gastrointestinal Drugs Market, by Application, 2018–2027 (USD Million)
11.1.6 North America: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.7 North America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
11.1.8 US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 US: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.8.3 US: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.8.4 US: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.8.5 US: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.9 Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 Canada: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.9.3 Canada: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.9.4 Canada: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.9.5 Canada: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.10 Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 Mexico: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.10.3 Mexico: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.10.4 Mexico: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.10.5 Mexico: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.2 Europe: Gastrointestinal Drugs Market
11.2.1 Overview
11.2.2 Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (USD Million)
11.2.3 Europe: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.2.4 Europe: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.2.5 Europe: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.2.6 Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.2.7 Europe: Gastrointestinal Drugs Market, by Country, 2018 & 2027 (%)
11.2.8 Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.8.1 Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.8.2 Germany: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.2.8.3 Germany: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.2.8.4 Germany: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.2.8.5 Germany: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.2.9 UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.9.1 UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.9.2 UK: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.2.9.3 UK: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.2.9.4 UK: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.2.9.5 UK: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.2.10 France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.10.1 France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.10.2 France: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.2.10.3 France: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.2.10.4 France: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.2.10.5 France: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.2.11 Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.11.1 Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.11.2 Spain: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.2.11.3 Spain: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.2.11.4 Spain: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.2.11.5 Spain: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.2.12 Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.12.1 Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.12.2 Italy: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.2.12.3 Italy: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.2.12.4 Italy: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.2.12.5 Italy: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.2.13 Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.13.1 Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.2.13.2 Rest of Europe: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.2.13.3 Rest of Europe: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.2.13.4 Rest of Europe: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.2.13.5 Rest of Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.3 Asia Pacific: Gastrointestinal Drugs Market
11.3.1 Overview
11.3.2 Asia Pacific: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (USD Million)
11.3.3 Asia Pacific: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.3.4 Asia Pacific: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.3.5 Asia Pacific: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.3.6 Asia Pacific: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.3.7 Asia Pacific: Gastrointestinal Drugs Market, by Country, 2018 & 2027 (%)
11.3.8 China: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.8.1 China: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.8.2 China: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.3.8.3 China: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.3.8.4 China: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.3.8.5 China: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.3.9 Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.9.1 Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.9.2 Japan: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.3.9.3 Japan: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.3.9.4 Japan: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.3.9.5 Japan: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.3.10 India: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.10.1 India: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.10.2 India: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.3.10.3 India: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.3.10.4 India: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.3.10.5 India: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.3.11 South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.11.1 South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.11.2 South Korea: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.3.11.3 South Korea: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.3.11.4 South Korea: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.3.11.5 South Korea: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.3.12 Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.12.1 Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.12.2 Australia: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.3.12.3 Australia: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.3.12.4 Australia: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.3.12.5 Australia: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.3.13 Rest of Asia-Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.13.1 Rest of Asia-Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.3.13.2 Rest of Asia-Pacific: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.3.13.3 Rest of Asia-Pacific: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.3.13.4 Rest of Asia-Pacific: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.3.13.5 Rest of Asia-Pacific: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.4 Middle East & Africa: Gastrointestinal Drugs Market
11.4.1 Overview
11.4.2 Middle East & Africa: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)
11.4.2.1 Middle East & Africa Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
11.4.2.2 Middle East & Africa Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.4.2.3 Middle East & Africa Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.4.2.4 Middle East & Africa Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.4.3 Middle East & Africa: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
11.4.3.1 Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.4.3.1.1 Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.4.3.2 Saudi Arabia Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
11.4.3.3 Saudi Arabia Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.4.3.4 Saudi Arabia Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.4.3.5 Saudi Arabia Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.4.3.6 UAE: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.4.3.6.1 UAE: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.4.3.7 UAE Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
11.4.3.8 UAE Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.4.3.9 UAE Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.4.3.10 UAE Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.5 South Africa Gastrointestinal Drugs Market Revenue and Forecasts to 2025 (US$ Mn)
11.5.1 South Africa Gastrointestinal Drugs Market Revenue and Forecasts To 2027 (US$ Mn)
11.5.1.1 South Africa Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
11.5.1.2 South Africa Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.5.1.3 South Africa Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.5.1.4 South Africa Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.6 Rest of Middle East and Africa Gastrointestinal Drugs Market Revenue and Forecasts to 2025 (US$ Mn)
11.6.1 Rest of Middle East and Africa Gastrointestinal Drugs Market Revenue and Forecasts To 2027 (US$ Mn)
11.6.1.1 Rest of Middle East and Africa Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
11.6.1.2 Rest of Middle East and Africa Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.6.1.3 Rest of Middle East and Africa Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.6.1.4 Rest of Middle East and Africa Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.7 South and Central America: Gastrointestinal Drugs Market
11.7.1 Overview
11.7.2 South and Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (USD Million)
11.7.3 South and Central America: Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
11.7.4 South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.7.5 South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.7.6 South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.7.7 South and Central America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
11.7.8 Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.7.8.1 Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.7.8.2 Brazil: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
11.7.8.3 Brazil: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.7.8.4 Brazil: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.7.8.5 Brazil: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.7.9 Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.7.9.1 Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.7.9.2 Argentina: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
11.7.9.3 Argentina: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.7.9.4 Argentina: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.7.9.5 Argentina: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.7.10 Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.7.10.1 Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.7.10.2 Rest of South and Central America: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
11.7.10.3 Rest of South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.7.10.4 Rest of South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.7.10.5 Rest of South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
12. Impact of COVID-19 Pandemic on Global Gastrointestinal Drugs Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
12.4 Rest of the World: Impact Assessment of COVID-19 Pandemic
13. Gastrointestinal Drugs Market–Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 Sanofi
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 GlaxoSmithKline plc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Johnson and Johnson Services, Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bausch Health
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 AstraZeneca
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Company Limited
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AbbVie Inc.
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Bayer AG
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Celltrion Healthcare Co.,Ltd.
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 LEXICON PHARMACEUTICALS, INC
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 Glossary of Terms
LIST OF TABLES
Table 1. North America Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 2. North America Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 3. North America Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 4. North America Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 5. US Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 6. US Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 7. US Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 8. US Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 9. Canada Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 10. Canada Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 11. Canada Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 12. Canada Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Mexico Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 14. Mexico Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 15. Mexico Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 16. Mexico Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 17. Europe Gastrointestinal Drugs Market, by Drug Class– Revenue and Forecast to 2027 (USD Million)
Table 18. Europe Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 19. Europe Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 20. Europe Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 21. Germany Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 22. Germany Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 23. Germany Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 24. Germany Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 25. UK Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 26. UK Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 27. UK Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 28. UK Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 29. France Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 30. France Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 31. France Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 32. France Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 33. Spain Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 34. Spain Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 35. Spain Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 36. Spain Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 37. Italy Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 38. Italy Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 39. Italy Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 40. Italy Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 41. Rest of Europe Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 42. Rest of Europe Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 43. Rest of Europe Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 44. Rest of Europe Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 45. Asia Pacific Gastrointestinal Drugs Market, by Drug Class– Revenue and Forecast to 2027 (USD Million)
Table 46. Asia Pacific Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 47. Asia Pacific Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 48. Asia Pacific Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 49. China Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 50. China Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 51. China Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 52. China Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 53. Japan Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 54. Japan Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 55. Japan Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 56. Japan Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 57. India Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 58. India Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 59. India Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 60. India Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 61. South Korea Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 62. South Korea Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 63. South Korea Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 64. South Korea Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 65. Australia Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 66. Australia Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 67. Australia Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 68. Australia Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 69. Rest of Asia-Pacific Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 70. Rest of Asia-Pacific Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 71. Rest of Asia-Pacific Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 72. Rest of Asia-Pacific Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 73. Middle East & Africa Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 74. Middle East & Africa Gastrointestinal Drugs Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 75. Middle East & Africa Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 76. Middle East & Africa Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 77. Saudi Arabia Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 78. Saudi Arabia Gastrointestinal Drugs Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 79. Saudi Arabia Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 80. Saudi Arabia Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 81. UAE Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 82. UAE Gastrointestinal Drugs Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 83. UAE Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 84. UAE Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 85. South Africa Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 86. South Africa Gastrointestinal Drugs Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 87. South Africa Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 88. South Africa Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 89. Rest of Middle East and Africa Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 90. Rest of Middle East and Africa Gastrointestinal Drugs Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)
Table 91. Rest of Middle East and Africa Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 92. Rest of Middle East and Africa Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 93. South and Central America: Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 94. South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 95. South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 96. South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 97. Brazil: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
Table 98. Brazil: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 99. Brazil: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 100. Brazil: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 101. Argentina: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
Table 102. Argentina: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 103. Argentina: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 104. Argentina: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 105. Rest of South and Central America: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
Table 106. Rest of South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 107. Rest of South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 108. Rest of South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 109. Organic Developments Done By Companies
Table 110. Inorganic Developments Done By Companies
Table 111. Glossary of Terms, Gastrointestinal Drugs Market
LIST OF FIGURES
Figure 1. Gastrointestinal Drugs Market Segmentation
Figure 2. Gastrointestinal Drugs Market – By Geography
Figure 3. Gastrointestinal Drugs Market Overview
Figure 4. Acid Neutralizers Segment Held Largest Share of Gastrointestinal Drugs Market
Figure 5. Asia Pacific to Show Significant Growth During Forecast Period
Figure 6. Gastrointestinal Drugs Market, by Geography (US$ Million)
Figure 7. Global Gastrointestinal Drugs Market – Leading Country Markets (US$ Million)
Figure 8. Global Gastrointestinal Drugs Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East and Africa (MEA) PEST Analysis
Figure 13. South and Central America (SCAM) PEST Analysis
Figure 14. Gastrointestinal Drugs Market Impact Analysis of Drivers and Restraint
Figure 15. Global Gastrointestinal Drugs Market – Revenue Forecast And Analysis – 2019- 2027
Figure 16. Global Gastrointestinal Drugs Market – By Geography Forecast and Analysis – 2019- 2027
Figure 17. Market Positioning Of Key Players In Global Gastrointestinal Drugs Market
Figure 18. Gastrointestinal Drugs Market Revenue Share, by Drug Class (2019 and 2027)
Figure 19. Acid Neutralizers: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. Antidiarrheal and Laxatives: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Anti-Inflammatory Drugs: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. Antiemetic and Antinauseants: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 23. Biologics: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 24. Others: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 25. Gastrointestinal Drugs Market Share, by Route of Administration, 2019 and 2027
Figure 26. Oral: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 27. Parenteral: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 28. Gastrointestinal Drugs Market Revenue Share, by Application (2019 and 2027)
Figure 29. Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 30. Crohn's Disease: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 31. Irritable Bowel Syndrome: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 32. Gastroenteritis: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 33. Celiac Disease: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 34. Others: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 35. Gastrointestinal Drugs Market Share, by Distribution Channel, 2019 and 2027
Figure 36. Hospital Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 37. Retail Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 38. Online Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 39. North America: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 40. North America Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 41. North America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
Figure 42. US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 43. Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 44. Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 45. Europe: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 46. Europe Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 47. Europe: Gastrointestinal Drugs Market, by Country, 2018 & 2027 (%)
Figure 48. Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 49. UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 50. France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 51. Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 52. Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 53. Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 54. Asia Pacific: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 55. Asia Pacific Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 56. China: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 57. Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 58. India: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 59. South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 60. Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 61. Rest of Asia-Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 62. Middle East & Africa: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 63. Middle East & Africa Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 64. Middle East & Africa: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
Figure 65. Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 66. UAE: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 67. South Africa Gastrointestinal drugs market Revenue and Forecasts to 2027 (US$ Mn)
Figure 68. Rest of Middle East and Africa Gastrointestinal drugs market Revenue and Forecasts to 2027 (US$ Mn)
Figure 69. South and Central America: Gastrointestinal Drugs Market , by Key Country – Revenue (2019) (USD Million)
Figure 70. South and Central America: Gastrointestinal Drugs Market, Revenue and Forecast to 2027 (USD Million)
Figure 71. South and Central America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
Figure 72. Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 73. Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 74. Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 75. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in North American Countries
Figure 76. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in European Countries
Figure 77. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in Asia Pacific Countries
Figure 78. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in Rest of the World
Figure 79. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies - Gastrointestinal Drugs Market
- Sanofi
- GlaxoSmithKline plc
- Johnson and Johnson Services, Inc.
- Bausch Health
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Bayer AG
- Celltrion Healthcare Co.,Ltd
- LEXICON PHARMACEUTICALS, INC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Oct 2020
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Oct 2020
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Oct 2020
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)
Oct 2020
Enteral and Parenteral Medical Nutrition Market
Forecast to 2028 - Global Analysis by Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer's Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole–Source), Form (Liquid, Powder, and Semi–Solid), Product Type (General and Disease–Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18–60 Years, 3–18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
Oct 2020
CIN & HR-HPV Treatment Market
Forecast to 2028 - Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)
Oct 2020
Pharmaceutical Fluid Handling Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering (Equipment & Solutions and Services), Tubing (Thermoplastic Elastomers, Polyvinyl Chloride, and Silicone), Application (Fluid Handling & Management, Fluid Preparation, Integration & Automation, Buffer Management, and Others), Usage (Cough Syrup, Intravenous Product, Complex Active Pharmaceutical Ingredients, and Others), and End User (Biotechnology Companies, Pharmaceutical & Medical Companies, and Others)
Oct 2020
Enteral Medical Nutrition Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]
Oct 2020
Glycomic Therapeutics Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]